Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion
Health Affairs · 2024
DOI: 10.1377/hlthaff.2024.00356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, 2024. Verfasst von Benedic Ippolito und 1 weiteren Autor:innen. Beteiligte Einrichtung: Benedic Ippolito (benedic.ippolito@aei.org), American Enterprise Institute, Washington, D.C. Hauptthemen laut MEDLINE: Health Expenditures, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Benedic Ippolito (benedic.ippolito@aei.org), American Enterprise Institute, Washington, D.C.
- Joseph F. Levy, Johns Hopkins University, Baltimore, Maryland.
Zitieren
APA
Ippolito, B., & Levy, J. F. (2024). Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion. Health Affairs. https://doi.org/10.1377/hlthaff.2024.00356
Vancouver
Ippolito B, Levy JF. Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion. Health Affairs. 2024. doi:10.1377/hlthaff.2024.00356
BibTeX
@article{Ippolito2024,
author = {Ippolito, Benedic and Levy, Joseph F},
title = {Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion},
journal = {Health Affairs},
year = {2024},
doi = {10.1377/hlthaff.2024.00356}
}
EUVIMED